Department of Pharmaceutical Technology, School of Pharmacy, Techno India University, Kolkata, 700091, India.
Department of Pharmaceutical Technology, NSHM Knowledge Campus, Kolkata, 124 B.L. Saha Road, Kolkata, West Bengal, 700053, India.
Med Oncol. 2024 Mar 5;41(4):84. doi: 10.1007/s12032-024-02303-x.
In developing new cancer medications, attention has been focused on novel epigenetic medicines called histone deacetylase (HDAC) inhibitors. Our understanding of cancer behavior is being advanced by research on epigenetics, which also supplies new targets for improving the effectiveness of cancer therapy. Most recently published patents emphasize HDAC selective drugs and multitarget HDAC inhibitors. Though significant progress has been made in emerging HDAC selective antagonists, it is urgently necessary to find new HDAC blockers with novel zinc-binding analogues to avoid the undesirable pharmacological characteristics of hydroxamic acid. HDAC antagonists have lately been explored as a novel approach to treating various diseases, including cancer. The complicated terrain of HDAC inhibitor development is summarized in this article, starting with a discussion of the many HDAC isotypes and their involvement in cancer biology, followed by a discussion of the mechanisms of action of HDAC inhibitors, their current level of development, effect of miRNA, and their combination with immunotherapeutic.
在开发新的癌症药物时，人们关注的是一种被称为组蛋白去乙酰化酶 (HDAC) 抑制剂的新型表观遗传药物。对表观遗传学的研究正在推进我们对癌症行为的认识，它也为提高癌症治疗效果提供了新的靶点。最近公布的专利强调了 HDAC 选择性药物和多靶点 HDAC 抑制剂。尽管在新兴的 HDAC 选择性拮抗剂方面取得了重大进展，但迫切需要找到具有新型锌结合类似物的新型 HDAC 阻断剂，以避免羟肟酸的不良药理特性。HDAC 拮抗剂最近被探索作为治疗各种疾病（包括癌症）的一种新方法。本文综述了 HDAC 抑制剂开发的复杂情况，首先讨论了许多 HDAC 同工型及其在癌症生物学中的作用，然后讨论了 HDAC 抑制剂的作用机制、它们的开发水平、miRNA 的影响以及它们与免疫治疗的结合。
